Beyond PSA: The Role of Prostate Health Index (phi)
Background: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient&...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/4/1184 |
id |
doaj-5d379298136a48089129498def3d6cdb |
---|---|
record_format |
Article |
spelling |
doaj-5d379298136a48089129498def3d6cdb2020-11-25T02:18:24ZengMDPI AGInternational Journal of Molecular Sciences1422-00672020-02-01214118410.3390/ijms21041184ijms21041184Beyond PSA: The Role of Prostate Health Index (phi)Matteo Ferro0Ottavio De Cobelli1Giuseppe Lucarelli2Angelo Porreca3Gian Maria Busetto4Francesco Cantiello5Rocco Damiano6Riccardo Autorino7Gennaro Musi8Mihai Dorin Vartolomei9Matteo Muto10Daniela Terracciano11Division of Urology, European Institute of Oncology, 20141 Milan, ItalyDivision of Urology, European Institute of Oncology, 20141 Milan, ItalyDepartment of Emergency and Organ Transplantation—Urology, Andrology and Kidney Transplantation Unit, University of Bari, 70124 Bari, ItalyDepartment of Urology, Abano Terme Hospital, 35031 Padua, ItalyDepartment of Urology, Sapienza University of Rome, 00185 Roma, ItalyDepartment of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Urology, Magna Graecia University of Catanzaro, 88100 Catanzaro, ItalyDivision of Urology, VCU Health System, Richmond, VA 23219, USADivision of Urology, European Institute of Oncology, 20141 Milan, ItalyDepartment of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, AustriaRadiotherapy Unit, “S. G. Moscati” Hospital, 83100 Avellino, ItalyDepartment of Translational Medical Sciences, University of Naples “Federico II”, 8031 Naples, ItalyBackground: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient’s quality of life suggested a strong need for tools able to identify clinically significant cancer at diagnosis. Multi-parametric magnetic resonance showed very good performance in pre-biopsy diagnosis. However, it is an expensive tool and requires an experienced radiologist. In this context, a simple blood-based test is worth investigating. In this context, researchers focused their attention on the development of a laboratory test able to minimize overdiagnosis without losing the identification of aggressive tumors. Results: Recent literature data on PCa biomarkers revealed a clear tendency towards the use of panels of biomarkers or a combination of biomarkers and clinical variables. Phi, the 4Kscore, and Stockholm3 as circulating biomarkers and the Mi-prostate score, Exo DX Prostate, and Select MD-X as urinary biomarker-based tests have been developed. In this scenario, phi is worthy of attention as a noninvasive test significantly associated with aggressive PCa. Conclusions: Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision-making. In this review, phi potentialities, limitations, and comparisons with other blood- and urinary-based tests were explored.https://www.mdpi.com/1422-0067/21/4/1184phiprostate canceroverdiagnosisclinical significance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matteo Ferro Ottavio De Cobelli Giuseppe Lucarelli Angelo Porreca Gian Maria Busetto Francesco Cantiello Rocco Damiano Riccardo Autorino Gennaro Musi Mihai Dorin Vartolomei Matteo Muto Daniela Terracciano |
spellingShingle |
Matteo Ferro Ottavio De Cobelli Giuseppe Lucarelli Angelo Porreca Gian Maria Busetto Francesco Cantiello Rocco Damiano Riccardo Autorino Gennaro Musi Mihai Dorin Vartolomei Matteo Muto Daniela Terracciano Beyond PSA: The Role of Prostate Health Index (phi) International Journal of Molecular Sciences phi prostate cancer overdiagnosis clinical significance |
author_facet |
Matteo Ferro Ottavio De Cobelli Giuseppe Lucarelli Angelo Porreca Gian Maria Busetto Francesco Cantiello Rocco Damiano Riccardo Autorino Gennaro Musi Mihai Dorin Vartolomei Matteo Muto Daniela Terracciano |
author_sort |
Matteo Ferro |
title |
Beyond PSA: The Role of Prostate Health Index (phi) |
title_short |
Beyond PSA: The Role of Prostate Health Index (phi) |
title_full |
Beyond PSA: The Role of Prostate Health Index (phi) |
title_fullStr |
Beyond PSA: The Role of Prostate Health Index (phi) |
title_full_unstemmed |
Beyond PSA: The Role of Prostate Health Index (phi) |
title_sort |
beyond psa: the role of prostate health index (phi) |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2020-02-01 |
description |
Background: Widespread use of prostate specific antigen (PSA) in screening procedures allowed early identification of an increasing number of prostate cancers (PCas), mainly including indolent cancer. Availability of different therapeutic strategies which have a very different impact on the patient’s quality of life suggested a strong need for tools able to identify clinically significant cancer at diagnosis. Multi-parametric magnetic resonance showed very good performance in pre-biopsy diagnosis. However, it is an expensive tool and requires an experienced radiologist. In this context, a simple blood-based test is worth investigating. In this context, researchers focused their attention on the development of a laboratory test able to minimize overdiagnosis without losing the identification of aggressive tumors. Results: Recent literature data on PCa biomarkers revealed a clear tendency towards the use of panels of biomarkers or a combination of biomarkers and clinical variables. Phi, the 4Kscore, and Stockholm3 as circulating biomarkers and the Mi-prostate score, Exo DX Prostate, and Select MD-X as urinary biomarker-based tests have been developed. In this scenario, phi is worthy of attention as a noninvasive test significantly associated with aggressive PCa. Conclusions: Literature data showed that phi had good diagnostic performance to identify clinically significant (cs) PCa, suggesting that it could be a useful tool for personalized treatment decision-making. In this review, phi potentialities, limitations, and comparisons with other blood- and urinary-based tests were explored. |
topic |
phi prostate cancer overdiagnosis clinical significance |
url |
https://www.mdpi.com/1422-0067/21/4/1184 |
work_keys_str_mv |
AT matteoferro beyondpsatheroleofprostatehealthindexphi AT ottaviodecobelli beyondpsatheroleofprostatehealthindexphi AT giuseppelucarelli beyondpsatheroleofprostatehealthindexphi AT angeloporreca beyondpsatheroleofprostatehealthindexphi AT gianmariabusetto beyondpsatheroleofprostatehealthindexphi AT francescocantiello beyondpsatheroleofprostatehealthindexphi AT roccodamiano beyondpsatheroleofprostatehealthindexphi AT riccardoautorino beyondpsatheroleofprostatehealthindexphi AT gennaromusi beyondpsatheroleofprostatehealthindexphi AT mihaidorinvartolomei beyondpsatheroleofprostatehealthindexphi AT matteomuto beyondpsatheroleofprostatehealthindexphi AT danielaterracciano beyondpsatheroleofprostatehealthindexphi |
_version_ |
1724882478559133696 |